Why Investing in the Horizons Marijuana Life Sciences ETF (TSX:HMMJ) Makes Perfect Sense

The Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) offers investors significant risk diversification. Here’s why this ETF is set to generate substantial returns in 2019 and beyond.

| More on:
Modern buildings in business district

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Several cannabis stocks have created significant wealth for investors. Aurora Cannabis has returned 1175% in the last five years, while Canopy Growth is up 1400% since August 2014. Tilray went public in July 2018 and has gained just 10%, while Cronos Group is up 1900% since December 2014.

But past returns mean nothing for a potential investor. How does one select the perfect stock to buy and hold for the long-term? Here is where the Horizons Marijuana Life Sciences ETF (TSX:HMMJ) comes into play. It has a basket of top cannabis stocks and diversifies investor risk.

Canopy Growth accounts for 11.8% of this ETF, followed by Aurora, Cronos, and Tilray at 11%, 9.7%, and 9.5%, respectively. Other top high-growth cannabis stocks such as Aphria and Hexo account for 6.2% and 4.3% of HMMJ. The top 10 holdings in HMMJ account for 71.5% of the ETF.

HMMJ is trading 42% below its 52-week high

The HMMJ ETF was listed in April 2017. It rose from $10.84 in April that year to $27 in September 2018. This ETF is now trading at $15.6 almost 42% below its 52-week high at writing. The recent pullback provides an opportunity for cannabis investors.

The global cannabis industry is estimated to grow at a robust rate. This industry is still in a nascent stage and investing in individual cannabis stocks will also mean a lot of volatility. While HMMJ will have a higher beta compared to traditional ETFs, investors will experience far lower volatility compared to individual stocks.

The HMMJ website states, “Unlike an investment in the stock of a single Marijuana company, HMMJ provides exposure to a diversified group of companies within the industry, reducing single security risk.”

Cannabis stocks have come under the scanner

We have seen that CannTrust stock has lost close to 80% in market value since March this year due to regulatory issues. Health Canada has suspended its license and the company is in the middle of an investigation by the Ontario Securities Commission as well.

Investors were spooked sending peer company shares lower in the recent past. Will this get other cannabis stocks under the regulatory lens? CannTrust accounts for just 1.9% of HMMJ and again limited significant investor loss.

HMMJ valued the North American cannabis market at $24.5 billion

The legal North America Marijuana market is estimated to reach $24.5 billion by 2021. This provides substantial growth opportunities for top cannabis stocks. Sales of Canopy, Aurora, Tilray, Aphria, Hexo, and Cronos are estimated grow by 194%, 369%, 315%, 189%, 1100%, and 288% respectively in the current fiscal year.

These robust growth rates are what attracts investors. Further, there is also significant potential for international expansion. Aurora and Canopy Growth are investing heavily in international markets and other players will look to do the same. The global cannabis industry is estimated to rise from $13.8 billion in 2018 to $66.6 billion in 2025.

HMMJ also has an annualized dividend yield of 4.8% which is more than impressive. This ETF has gained 44% since April 2017 and will most likely be a solid bet for long term cannabis investors.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. 

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »